Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Assets (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Assets for 16 consecutive years, with $706.6 million as the latest value for Q4 2025.

  • Quarterly Assets fell 31.24% to $706.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $706.6 million through Dec 2025, down 31.24% year-over-year, with the annual reading at $706.6 million for FY2025, 31.24% down from the prior year.
  • Assets for Q4 2025 was $706.6 million at Myriad Genetics, down from $728.1 million in the prior quarter.
  • The five-year high for Assets was $1.4 billion in Q2 2021, with the low at $677.3 million in Q2 2025.
  • Average Assets over 5 years is $1.1 billion, with a median of $1.2 billion recorded in 2023.
  • The sharpest move saw Assets fell 1.9% in 2023, then tumbled 37.58% in 2025.
  • Over 5 years, Assets stood at $1.3 billion in 2021, then dropped by 9.24% to $1.2 billion in 2022, then fell by 4.35% to $1.1 billion in 2023, then dropped by 10.37% to $1.0 billion in 2024, then plummeted by 31.24% to $706.6 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $706.6 million, $728.1 million, and $677.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.